Amy Klobuchar Quotes

If you go to the FDA with a drug that's only meant to treat 50 people, and it's a 95 percent cure rate, you'll get your drug approved.

The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.

On the third stage is used for medicine, it is not known to the public.

I agree, the world would be a better place if doctors were less enthusiastic about adopting very new drugs.

Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

I keep encouraging the pharmaceutical companies to put more money into R&D.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

While I am prepared to look at all options and to think 'outside the box' for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public.

To start with, pharma was an industry based on innovation, drug discovery.

I've heard drug experts say they believe if penicillin were discovered today, the FDA wouldn't license it.

There's always going to be the need for new medications, better medications.

I think FDA's concerns are patient-safety.

Medicines are unusual commodities. Important drugs can save the lives and protect the health of millions. Their consumption can bring huge benefits, by helping patients to avoid infection and preventing serious damage to the economies of families, nations and even humanity at large.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

I want to make a drug. I want the science to be more than imaginary, where I think, 'We're learning these fundamental principles, blah, blah, blah, blah, blah.' I think we are doing that, but I want to do something really practical. I want to actually, in my lifetime, help people.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

When the FDA forces an old drug off the market, patients have very little say in the matter. Patients have even less of a say when the FDA chooses not to approve a new drug. Instead, we are supposed to rely on the FDA's judgment and be grateful. But can the FDA really make a choice that is appropriate for everyone? Of course not.

Efforts to approach zero risk through exhaustive pre-release testing are extremely expensive and time-consuming. New drugs are delayed in reaching those who need them, and marginal drugs may not be developed at all.

When you work in the pharmaceutical industry you realize that there's a lot out of people's control, and there's ways that people can be helped.

There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company.

The higher cost of getting a generic drug approved by regulators means that many old medicines don't face competitors. It's only after substantial price hikes that these drugs offer enough revenue to offset the rising generic entry costs, and start to entice competition.

Rushing blindly towards unproven drugs can be disastrous and result in countless more deaths.

If my drug Ragaglitazar had been successful, we would have been getting royalties of thousands of crore rupees every year.